eCite Digital Repository

A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease

Citation

Severi, G and Fitzgerald, LM and Muller, DC and Pedersen, J and Longano, A and Southey, MC and Hopper, JL and English, DR and Giles, GG and Mills, J, A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease, Cancer Medicine, 3, (5) pp. 1266-74. ISSN 2045-7634 (2014) [Refereed Article]


Preview
PDF
121Kb
  

Copyright Statement

Copyright 2014 The Authors. Licensed under Creative Commons Attribution 3.0 Unported (CC BY 3.0) http://creativecommons.org/licenses/by/3.0/

DOI: doi:10.1002/cam4.281

Abstract

Only a minority of prostate cancers lead to death. Because no tissue biomarkers of aggressiveness other than Gleason score are available at diagnosis, many nonlethal cancers are treated aggressively. We evaluated whether a panel of biomarkers, associated with a range of disease outcomes in previous studies, could predict death from prostate cancer for men with localized disease. Using a case-only design, subjects were identified from three Australian epidemiological studies. Men who had died of their disease, "cases" (N = 83), were matched to "referents" (N = 232), those who had not died of prostate cancer, using incidence density sampling. Diagnostic tissue was retrieved to assess expression of AZGP1, MUC1, NKX3.1, p53, and PTEN by semiquantitative immunohistochemistry (IHC). Poisson regression was used to estimate mortality rate ratios (MRRs) adjusted for age, Gleason score, and stage and to estimate survival probabilities. Expression of MUC1 and p53 was associated with increased mortality (MRR 2.51, 95% CI 1.14-5.54, P = 0.02 and 3.08, 95% CI 1.41-6.95, P = 0.005, respectively), whereas AZGP1 expression was associated with decreased mortality (MRR 0.44, 95% CI 0.20-0.96, P = 0.04). Analyzing all markers under a combined model indicated that the three markers were independent predictors of prostate cancer death and survival. For men with localized disease at diagnosis, assessment of AZGP1, MUC1, and p53 expression in diagnostic tissue by IHC could potentially improve estimates of risk of dying from prostate cancer based only on Gleason score and clinical stage.

Item Details

Item Type:Refereed Article
Keywords:Prostate Cancer Biomarkers
Research Division:Medical and Health Sciences
Research Group:Oncology and Carcinogenesis
Research Field:Cancer Genetics
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cancer and Related Disorders
UTAS Author:Fitzgerald, LM (Dr Liesel Fitzgerald)
ID Code:104115
Year Published:2014
Web of Science® Times Cited:14
Deposited By:Menzies Institute for Medical Research
Deposited On:2015-11-03
Last Modified:2017-11-06
Downloads:278 View Download Statistics

Repository Staff Only: item control page